The Board (the ‘Board')of Directors (the ‘Directors') of Sinco Pharmaceuticals Holdings Limited (the ‘Company', together with its subsidiaries, the ‘Group') that with effect from 29 March 2023, Mr. Huang Xiangbin (‘Mr. Huang') has tendered to the Board his resignation as a co-chief executive officer of the Company due to the need to devote more time to his other business commitment. Mr. Jin Min ("Mr. Jin"), will become the chief executive officer of the Company. Mr. Jin's term of office, remuneration, other titles and positions remain unchanged.